Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to keep in mind that Vertex retains 60% of Casgevy profit while CRISPR ...
A miracle baby who was treated with a pioneering gene-therapy at CHOP has reached a major milestone as he took his first ...
The baby saved from a rare disease by a first-ever personalized gene fix has reached a big milestone, taking his first steps ...
CRISPR is one of the most revolutionary technologies of the modern era, and now it's being used to bring back long-lost genes ...
CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.
Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...
The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that ...
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments ahead of Christmas, on December 23, ...
Scientists from Kolkata-based Bose Institute have created GlowCas9 -- a CRISPR protein that lights up while performing gene ...
Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback